This British Thoracic Society (BTS) Clinical Statement addresses the diagnosis, evaluation
and management of pulmonary sarcoidosis, with each section summarised with key clinical …

A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a
progressive-fibrosing phenotype, which is associated with a deterioration in lung function …

Thoracic sarcoidosis is the most common form of sarcoidosis, encompassing a
heterogeneous group of patients with a wide range of clinical features and associated …

Sarcoidosis is a multi-system disease of unknown etiology characterized by granuloma
formation in various organs (especially lung and mediastinohilar lymph nodes). In more than …

Understanding the mechanisms of fibrotic transformation in sarcoidosis enhances clinical
care and facilitates development of novel therapeutic options. The impact of these findings in …

Background Sarcoidosis is a chronic multisystem disease of unknown etiology characterized
by noncaseating granulomas that most often involves the lungs, but frequently has …

Introduction: The pathogenesis of sarcoidosis is not yet completely understood, although in
recent years our knowledge has made considerable progress. Areas covered: This review …

This is a prospective, open-label, proof-of-concept study of tofacitinib, a Janus kinase
inhibitor, as a steroid-sparing therapy in corticosteroid-dependent pulmonary sarcoidosis …

Background: Pulmonary sarcoidosis patients who get disease progression despite
corticosteroid treatment or can't tolerate corticosteroid required second-line drug …

Introduction: Sarcoidosis is a multi-organ disease with a wide range of clinical
manifestations and outcomes. A quarter of sarcoidosis patients require long-term treatment …